Novartis wins full FDA approval for Fabhalta in IgAN (NVS:NYSE)
Novartis (NVS) wins full FDA approval for the kidney disease drug, Fabhalta, to slow kidney function decline in adults with primary IgA nephropathy. Read more here.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Novartis (NVS) wins full FDA approval for the kidney disease drug, Fabhalta, to slow kidney function decline in adults with primary IgA nephropathy. Read more here.
Novartis wins full FDA approval for Fabhalta in IgAN (NVS:NYSE) | Seeking Alpha
Save
Play
(
1min
)
Comments
TBE/iStock Editorial via Getty Images
Novartis (
NVS
) on Friday announced that the U.S. FDA issued full approval for its kidney disease therapy. Fabhalta (iptacopan) for primary immunoglobulin A nephropathy, an autoimmune condition also known as Berger disease.
The oral Factor B inhibitor with the FDA
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Entering text into the input field will update the search result below
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Global stocks remain constructive as semis sell off â HSBCâs Max Kettner
HSBCâs Max Kettner sees global equities resilient amid tech weakness, with semis signaling buys and Europe/Japan opportunities.
Q2 earnings: Top and bottom Quant-rated materials stocks (XLB:NYSEARCA)
Track Q2 earnings for materials stocks: XLB beats S&P 500 YTD.
AbbVie granted EU nod for Boey anti-wrinkle therapy (ABBV:NYSE)
AbbVie (ABBV) unit Allergan wins EU approval for the Boey anti-wrinkle injectable for temporary improvement of frown lines across 30 European countries. Read more here.
Anfield Universal Fixed Income ETF declares $0.0119 dividend (BATS:AFIF)
Anfield Universal Fixed Income ETF (AFIF) declares $0.0119/share monthly dividend. Payable July 22; for shareholders of record July 17; ex-div July 17. See AFIF
